Talking Biotech with Dr. Kevin Folta

Chronic inflammation goes hand-in-hand with many diseases, complicating symptoms and affecting routes of treatment. What is the molecular basis of inflammation, and can it be targeted by new drugs? Scientists have studied the molecular basis of the inflammatory response and have identified specific proteins that complex to initiate the response. New drugs are showing promise in breaking the inflammatory cascade. Studies of genealogical records revealed additional targets that modify known genetic pathways that contribute to Alzheimer's, cancers and cardiovascular disease. Dr. David Bearss from Halia Therapeutics explains the roles of inflammation and the mechanisms behind several drug candidates that are targeting chronic inflammation. 

What is Talking Biotech with Dr. Kevin Folta?

Talking Biotech is a weekly podcast that uncovers the stories, ideas and research of people at the frontier of biology and engineering.

Each episode explores how science and technology will transform agriculture, protect the environment, and feed 10 billion people by 2050.

Interviews are led by Dr. Kevin Folta, a professor of molecular biology and genomics.